HMG: Molecular Structure

Molecular Structure and Properties#

HMG is a peptide whose molecular structure and properties have been characterized through analytical chemistry and structural biology studies.

Amino Acid Sequence#

Scope and nomenclature Here, “HMG” is interpreted as human high mobility group box 1 (HMGB1), historically called HMG‑1. HMGB1 is the prototypical HMGB family member and the one most frequently described at the sequence/structure/physicochemical level.

Amino acid sequence, length, and domain boundaries HMGB1 is a single polypeptide of 215 amino acids (~24.9 kDa). It comprises two homologous DNA‑binding HMG boxes (A and B) followed by a highly acidic C‑terminal tail. Consensus residue ranges from primary literature and curated sequence references place box A roughly from Gly2 to Ile79, box B from Phe89 to Arg163, with an acidic tail spanning approximately 185/186–215; two nuclear localization sequences are found at aa 28–44 and 179–185. For the definitive primary sequence, UniProt accession P09429 should be used.

Structural features of the HMG boxes Each HMG box is a compact, basic domain with a characteristic L‑shaped fold formed by three α‑helices. The angle between the arms of the L is on the order of ~80°, and the fold presents a basic surface that binds the DNA minor groove, promoting or stabilizing DNA bending. In HMG1 B‑domain structures, the helices occupy approximate spans corresponding to residues 13–29, 34–48, and 50–74 of the expressed fragment. HMGB1 binds DNA largely without strict sequence specificity but prefers distorted substrates such as four‑way junctions and hemicatenated loops, and it can induce bends in duplex DNA. Identified intercalating residues that contribute to bending include Phe37 (box A) and Ile121 (box B).

Physicochemical properties and charge distribution HMGB1 is markedly dipolar: its A and B boxes are positively charged, whereas the C‑terminal tail is a 30‑residue, glutamate/aspartate‑rich segment ending with a DDDDE motif. Electrostatic intramolecular interactions between the acidic tail and basic boxes confer autoinhibition of DNA binding and increase protein stability; removal of the tail increases box–DNA affinity but reduces thermal/chemical stability and modestly decreases the net DNA‑bending angle compared with full‑length protein. A computed/reported isoelectric point is approximately 5.7, with an estimated net charge of around −4.6 at pH 7.1 for the full‑length protein, values driven by the acidic tail. The dipolar nature underlies many interaction and purification behaviors.

Functionally important residues and PTMs affecting charge/conformation Three conserved cysteines, C23 and C45 in box A and C106 in box B, constitute a redox switch: cytokine‑like activity requires a C23–C45 disulfide with C106 reduced; terminal oxidation (sulfonyl) abolishes activity. Reports also describe acetylation (e.g., K82), phosphorylation, ADP‑ribosylation, methylation, and putative N‑glycosylation motifs (N37, N134/N135), with PTM patterns differing by source and influencing localization, stability, and DNA interactions.

Concise summary artifact

Notes on sequence reference For the exact amino acid sequence used in most studies and for curated PTM annotations, consult UniProt P09429; domain boundary definitions differ slightly among structural constructs, but the consensus ranges above capture the commonly used limits.

Stability and Formulation#

We interpret HMG as HMG‑CoA reductase inhibitors (statins), and summarize their stability with emphasis on pH, temperature, degradation pathways, and formulation.

pH stability

• Lactone statins (e.g., simvastatin) undergo hydrolysis to the β‑hydroxy acid; base-catalyzed ring opening can be partially reversible on drying, whereas acid can drive further degradation. In solution and formulations, hydrolysis risk increases with inappropriate pH and temperature.
• Atorvastatin shows clear pH‑dependent instability: faster degradation in acid (first-order, k ≈ 1.88 × 10−2 s−1 at tested conditions) than in base (zero-order, k ≈ 2.35 × 10−4 mol L−1 s−1). Photostability and oxidative stress are also relevant per ICH Q1B testing.

Temperature sensitivity

• Simvastatin exhibits thermal decomposition under oxidative atmospheres with onset around 353 K; exclusion of oxygen (inert atmosphere/reduced pressure) suppresses decomposition. Heat and humidity accelerate loss generally for statins.
• Processing in polymer matrices (e.g., PEG 6000) shows that heating to 423 K can amorphize simvastatin but risks thermal decomposition; subsequent compression can induce partial recrystallization, affecting stability and dissolution over storage.

Degradation pathways

• Principal routes include hydrolysis (lactone ring opening for lactone statins), oxidation (oxygen/peroxides; metal‑catalyzed), photolysis (notably strong for simvastatin), and dehydration products under acidic/thermal stress. Excipients and atmospheric factors (O2, Fe3+, UV) modulate these pathways.

Formulation considerations

• Protect from acid/base extremes, light, oxygen, and humidity via choice of pH, antioxidants, chelators, and barrier packaging. Some excipients and coatings can protect (e.g., coatings, antioxidants such as ascorbate/BHA/BHT), but others may catalyze photo‑oxidative degradation; compatibility testing is essential.
• Solid-state products may be more robust than solutions to certain stresses; however, processing history (heat, compression) can induce amorphization/recrystallization that changes stability. Oxygen‑controlled manufacturing and low‑temperature processing mitigate thermal/oxidative degradation risks.

Overall, statins are intrinsically sensitive to hydrolysis (pH/temperature dependent), oxidation, and light; thermal stability improves markedly under inert atmospheres. Formulation strategies should therefore integrate pH control, oxygen and light exclusion, judicious excipient selection (including antioxidants/chelators), and careful thermal/mechanical processing to maintain solid-state integrity and minimize degradation.

Pharmacokinetics#

Absorption In rats, exogenous HMG has been administered both orally (in drinking water) and intraperitoneally (i.p.). Under matched nominal daily doses (0.12 mmol/animal/day), i.p. dosing produced larger pharmacodynamic effects than oral dosing, indicating lower effective oral exposure/bioavailability with the aqueous drinking‑water regimen used; absolute oral bioavailability (F) was not directly measured. After oral or i.p. administration of [14C]‑HMG, systemic distribution of radioactivity was observed (see Distribution), confirming absorption from the gut after oral dosing, but at lower organ levels than after i.p. dosing.

Distribution After a single [14C]‑HMG dose in rats, radioactivity distributed to multiple organs, with relatively greater accumulation in liver and kidney versus other tissues; measurable activity also occurred in brain, skeletal muscle, adipose tissue, lung, and gut. Organ radioactivity was higher after i.p. than oral dosing, and higher in diabetic than control rats. Direct brain exposure by intracerebroventricular administration in neonatal rats produced biochemical effects detectable at 1 and 20 days post‑dose, confirming target engagement in CNS when directly delivered; this model does not provide systemic PK parameters.

Metabolism Hepatic mitochondrial metabolism is supported by enzymology and in vivo data. Rat liver contains a succinyl‑CoA:3‑hydroxy‑3‑methylglutarate CoA transferase activity that converts HMG to HMG‑CoA, which can be further metabolized to acetoacetate; this metabolism is consistent with HMG’s participation in cholesterol/ketone pathways and with its known inhibitory pharmacodynamics on HMG‑CoA reductase. In HMG‑CoA lyase deficiency (human), tissue accumulation of HMG occurs with high urinary excretion; levels rise during metabolic decompensation, consistent with impaired downstream metabolism.

Elimination and routes of excretion Human observational data from HMG‑CoA lyase deficiency show high urinary excretion of HMG, which spikes during acute illness and decreases with dietary/illness management, indicating renal elimination is a major route for the free acid in vivo. In a rodent hepatotoxicity model (valproate plus high‑fat diet), urinary HMG increased, again supporting renal excretion as the measurable outlet for excess systemic HMG. Specific quantitative renal clearance values, biliary fractions, or transporter identities were not reported in the retrieved texts.

Half‑life and time course In the rat [14C]‑HMG study, organ radioactivity after either i.p. or oral dosing declined substantially within 24 hours, with only small amounts remaining in liver and kidney at 24 h, indicating that most of the administered dose is cleared from organs within a day. A plasma half‑life (t1/2) was not reported.

Oral bioavailability No study reported an absolute oral bioavailability (F) for HMG. Comparative data (oral vs i.p. at the same nominal daily dose) showed weaker pharmacodynamic effects after oral exposure in drinking water, consistent with lower effective bioavailability in that regimen.

Analytical considerations supporting disposition claims Urine is considered the preferred clinical matrix for organic acids, including HMG, because kidney concentrates these acids; validated GC/MS and LC‑MS/MS methods exist, with low detection limits for HMG, supporting observations of high urinary excretion in human disorders and experimental models.

Summary PK profile of HMG (3‑hydroxy‑3‑methylglutaric acid) • Absorption: Orally absorbed in rats (systemic radioactivity detected after oral [14C]‑HMG), but with lower effective exposure than i.p. dosing under the studied conditions; absolute F not measured. • Distribution: Highest to liver and kidney; also present in brain, muscle, adipose, lung, gut; greater hepatic/renal accumulation in diabetic rats; organ levels largely diminish by 24 h. • Metabolism: Hepatic mitochondrial activation to HMG‑CoA via succinyl‑CoA:HMG CoA‑transferase, with conversion to acetoacetate; consistent with participation in ketone/cholesterol metabolism. • Elimination: Predominantly renal excretion of the free acid inferred from high urinary levels in human HMG‑CoA lyase deficiency and from experimental models; quantitative renal clearance and biliary fractions not reported. • Half‑life: Not reported in plasma; organ radioactivity after a single dose largely cleared within 24 h in rats. • Bioavailability: Absolute oral bioavailability not reported; oral dosing showed lower impact than i.p. at matched nominal dose, consistent with reduced effective bioavailability in the studied regimen.

Key limitations Direct quantitative PK parameters (plasma t1/2, Cmax, AUC, CL, Vd, absolute oral F) were not available in the retrieved texts. The best evidence combines radiotracer organ distribution/time‑course in rats with clinical urinary excretion patterns and hepatic mitochondrial metabolism. Future targeted studies would be required to define plasma PK and transporter involvement.

Related Reading#

• HMG overview and research guide
• Peptides similar to HMG
• HMG research evidence